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Objective: To describe the causes of mortality among the HIV-infected in southern India in the era
of highly active antiretroviral therapy (HAART).
Methods: Analyses of this patient cohort were conducted using the YRG Centre for AIDS Research
and Education HIV Natural History Observational Database. Causes of death were then indivi-
dually confirmed by patient chart review.
Results: Sixty-nine deaths occurred within the inpatient unit; 25% were female and the median
age of the 69 patients was 34 years. Over half of the patients (55%) died within three months of
initiating HAART. At the time of enrollment into clinical care, the median CD4 cell count was 64
cells/ml (interquartile range (IQR) 37—134). At the time of initiating HAART, the median CD4 cell
count was 58 cells/ml (IQR 31—67) for patients who died within 3 months of initiating HAARTand
110 cells/ml (IQR 77—189) for patients who died more than 3 months after initiating HAART. Close
to three-fourths of patients (70%) died from an AIDS-defining illness (ADI). Themajor ADI causes of
death included Pneumocystis jiroveci pneumonia (22%), extrapulmonary tuberculosis (19%), CNS
toxoplasmosis (12%), and pulmonary tuberculosis (10%). A tenth of patients died from cerebro-
vascular infarcts. Three patients (4%) died from non-Hodgkin lymphoma.
Conclusions: AIDS-related events continue to be the major source of mortality among the HIV-
infected in southern India in the era of HAART. This mortality pattern justifies increased proactive
efforts to identify HIV-infected patients and initiate HAART earlier, before patients present to
care with advanced immunodeficiency.
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Studies conducted in the developed world in the era of highly
active antiretroviral therapy (HAART) have repeatedly docu-
mented that AIDS-related events are no longer the major
causes of death.1—5 However the mortality pattern may vary
in resource-limited settings where patients often present to
clinical care with advanced immunodeficiency and where
opportunistic infections, primarily tuberculosis, are ram-
pant.6—9 Despite the fact that generic antiretroviral therapy
(ART) is effective in resource-limited settings,10 investigating
the emerging causes of death in the era of HAART can allow
clinicians to preemptively manage the clinical complications
of HIV-infected patients.
Earlier studies have documented the changing natural
history of HIV disease in the pre- and post-HAART eras in
southern India.11,12 However, data remain limited on the
causes of death among HIV-infected Indians, particularly in
the HAART era.13,14 The current study was undertaken to
determine the causes of death among the HIV-infected in
southern India who had initiated HAART. The findings of the
current study are timely in assessing whether the causes of
mortality among HIV-infected patients in resource-limited
settings have changed as an increasing number of HIV-
infected patients gain access to HAART.
Methods
Setting
The YRG Center for AIDS Research and Education (YRG
CARE) in Chennai is a large non-profit medical and research
institution. Since 1996, it has provided comprehensive care
for over 12 000 HIV-infected individuals. All patients are
treated according to World Health Organization (WHO)
treatment guidelines.15 Co-trimoxazole prophylaxis was
initiated for all patients as per WHO guidelines.16 Patients
were advised to initiate antiretroviral therapy when CD4
counts reached <200 cells/ml or when CD4 counts ranged
between 200 and 350 cells/ml with an AIDS-defining illness
(ADI). Nevirapine (NVP)-based regimens, which are the
least expensive and most widely available, were used in
first-line therapies. Patients were seen every 3 months or
as clinically indicated. CD4 monitoring was done every 3 to
6 months.
Patients
Patients who were older than 18 years of age, attending the
YRG CARE clinic between February 1996 and January 2008,
and ART-naı¨ve before initiation of HAARTwere included in the
analysis. Data were collected under the approval of YRG
CARE’s free-standing institutional review board. Analyses
used the YRG CARE HIV Natural History Observational Data-
base.11,12 This database is updated daily by research nurses
who are trained to use a validated prospective data collec-
tion instrument, which includes demographics; clinical
assessments, current treatment regimens, and adverse
events (AEs); laboratory data, including hemoglobin, liver
and renal function tests, CD4 cell counts, and plasma viral
load (PVL); and genotypic testing, if available. All patientswhose cause of death was assigned as cerebrovascular infarct
underwent computed tomography (CT).
Definitions
The 1993 Centers for Disease Control and Prevention (CDC)
case definitions were used with definitive diagnostic methods
for cryptosporidiosis, cryptococcosis, and Mycobacterium
tuberculosis, and presumptive diagnostic methods for Pneu-
mocystis jiroveci pneumonia (PCP), cytomegalovirus retini-
tis, and toxoplasmosis.17 The most recent National Institutes
of Health (NIH) definitions of AIDS-associated AEs were
employed for diagnosis.18 The primary cause of death was
confirmed through patient chart review conducted by a staff
physician.
Statistical analysis
Descriptive statistics were calculated with mean and stan-
dard deviation for variables that were normally distributed;
the median and interquartile range (IQR) were calculated for
variables influenced by extreme variables. To compare pro-
portions, Chi-square statistics and independent t-tests were
used. Survival analysis after initiating HAARTwas conducted
using the Kaplan—Meier method. All statistical analyses were
performed using SPSS software (version 13.0; SPSS, Chicago,
IL, USA). A p-value less than 0.05 was considered statistically
significant.
Results
Between February 1996 and January 2008, 4848 ART-naı¨ve
adult patients (>18 years of age) initiated HAART at YRG
CARE. The median CD4 cell count at the time of initiating
HAARTwas 142 cells/ml (IQR 65—261); the median time from
enrollment to initiating HAART was 27 days (IQR 4—237).
Among HAART initiated patients, 155 (3%) consequently
died, and of these, 69 died within the inpatient unit. Only
these 69 patients are included in the subsequent analyses.
Twenty-five percent were female; the median age of all 69
patients was 34 years. Almost all participants (>95%) had
acquired HIV infection through heterosexual transmission.
The most common HAART regimens included: lamivudine
(3TC) + stavudine (d4T) + nevirapine (NVP) (36%), 3TC
+ d4T + efavirenz (EFV) (33%), and 3TC + NVP + zidovudine
(AZT) (6%). Over half (55%) of the patients died within 3
months of initiating HAART, 10% of patients died at between 3
and 6 months of initiating HAART, and 35% of patients died
more than 6 months after initiating HAART (Table 1).
At the time of enrollment into clinical care, the median
CD4 cell count was 64 cells/ml (IQR 37—134) and the median
hemoglobin was 9.7 g/dl (IQR 7.8—11.1). The most common
opportunistic infections at enrollment were pulmonary
tuberculosis (14%) and PCP (6%). At the time of initiating
HAART, the median CD4 cell count was 58 cells/ml (IQR 31—
67) for patients who died within 3 months of initiating HAART
and 110 cells/ml (IQR 77—189) for patients who died more
than 3 months after initiating HAART; this difference was not
statistically significant ( p = 0.07). The most common inci-
dent opportunistic infection after initiating HAART was pul-
monary tuberculosis (6%). The most common AEs to therapy
Table 1 Demographic and clinical characteristics of
patients at enrollment to care and at initiation of highly
active antiretroviral therapy (HAART) (N = 69)
Characteristic Median (IQR) or %
Men 75%
Women 25%
Age, years 34 (29—39)
At enrollment to care
CD4 cell count, cells/ml 64 (37—134)











Hepatitis B virus 3%
Hepatitis C virus 3%
Anemia 4%
Non-Hodgkin lymphoma 1%
Median duration on HAART (months) 5.35
CD4 cell count at the time of initiating HAART, cells/ml
Died <3 months 58 (31—67)






Pneumocystis jiroveci pneumonia 3%
Extrapulmonary tuberculosis 3%





Immune reconstitution syndrome 3%
Died after initiating HAART
0—3 months of initiating HAART 55%
3—6 months of initiating HAART 10%
>6 months of initiating HAART 35%
IQR, interquartile range.
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The median duration on HAART was 5 months (Table 1).
Table 2 outlines the reasons for death, median time of
treatment prior to death, and median CD4 at the time of
initiating HAARTand at the time of death for the 69 patients.
The major ADI causes of death included PCP (22%), extra-
pulmonary tuberculosis (19%), CNS toxoplasmosis (12%), and
pulmonary tuberculosis (10%). A tenth of patients died from
cerebrovascular infarcts. Three patients (4%) died from non-
Hodgkin lymphoma.
Patients who died more than 3 months after initiating
HAART had significantly higher CD4 cell counts at the time ofdeath compared to patients who died within 3 months of
initiating HAART (138 cells/ml vs. 59 cells/ml; p = 0.04).
Patients who died more than 3 months after initiating HAART
and patients who died within 3months of initiating HAART did
not experience statistically significant differences in median
duration of hospitalization at the time of death nor in the
incidence of opportunistic infections.
Discussion
The present study documents that in the era of HAART in
southern India, AIDS-related illnesses (70%) continue to be
the major source of patient mortality. The high frequency
of death due to ADIs, particularly tuberculosis, can be
attributed to a low median CD4 cell count at the time
of initiating ART. A study among West African HIV patients
similarly documented a high mortality soon after initiating
HAARTand the leading role of mycobacterial infections as a
cause of death.7 Many of the patients in the current study
also had low hemoglobin levels after initiating HAART,
confirming the strong relationship between anemia and
death.19,20
The findings of the current study contrast with recent
studies conducted in developed countries, in which improve-
ments in HIV treatment have led to proportionately fewer
deaths from ‘typical’ HIV-related illnesses and increasing
deaths attributable to cardiac disease, trauma, and liver
disease.1,3,21,22 We documented a high frequency of bacterial
and fungal infections in the time period before the immune
restorative effects of HAART, with Mycobacterium tubercu-
losis and PCP accounting for half of all patient deaths (see
Figure 1). A recent study from Brazil identified tuberculosis as
the leading cause of death (9%), which was responsible for
more than twice as many deaths as PCP (5%).6 A retrospective
analysis among HIV-infected patients in the USA found that
PCP was the major cause of death in the era of HAART, which
was attributed to the fact that more than 50% of patients who
died were not receiving HAART.23 Timely prophylaxis and
effective treatment of opportunistic infections must be an
integral part of any antiretroviral treatment program, espe-
cially in resource-limited settings where opportunistic infec-
tions are rampant.
The current analyses were limited to inpatient causes of
death. Though three-fourths of patients who died were men,
three-fourths of all patients who initiated HAART were also
men. Prior studies at our center have documented that men
tend to present to care with advanced immunodeficiency,
andwomen are diagnosed earlier due to screening of partners
(symptomatic men) or as part of antenatal testing.11,12
Though we documented the number of deaths occurring
outside of the clinic, the definitive causes of death could
not be obtained at the time of death and hence these cases
were excluded from this analysis. Discernment of the precise
causes of death is always a challenge. Routine autopsies are
not performed at our institution; however, we undertook a
thorough analysis of all available clinical and laboratory data
to confirm the cause of death.
The findings of the present study suggest that despite the
wider introduction of HAART in resource-limited settings,
mortality continues to occur due to advanced immunodefi-
ciency soon after starting therapy. A study comparing mor-
tality patterns between high- and low-income countries
Table 2 Causes of death andmedian CD4 cell count at the time of initiating highly active antiretroviral therapy (HAART) and at the
time of death (N = 69)













Pulmonary 10 115 (23—233) 31 (19—62) 29 (22—70)
Meningitis 6 22 (16—26) 167 (115—218) 130 (53—277)
Abdominal 9 107 (42—354) 64 (51—111) 95 (80—108)
Other extrapulmonary 4 50 (36—158) 95 (78—338) 74 (63—84)
Pneumocystis jiroveci pneumonia 22 8 (3—64) 52 (44—130) 50 (22—65)
CNS toxoplasmosis 12 134 (61—310) 63(54—93) 92 (61—129)
Cryptococcal meningitis 6 388 (3—999) 39 (23—91) 24 (18—35)
Cryptosporidial diarrhea 3 388 (57—703) 323 (313—385) 235 (216—300)
Viral encephalitis 1 18 7 NAa
Bacterial meningitis 1 25 NAa NAa
Progressive multifocal
leukoencephalopathy
1 22 17 17
Cerebrovascular infarct
(neurological complication)
10 187 (16—307) 142 (84—162) 96 (61—233)
Bacteremia 2 655 176 86
HIV co-infections
Hepatitis B 1 88 26 56
Hepatitis C 1 6 62 NAa
Malignancies
Non-Hodgkin lymphoma 4 115 (38—213) 65 (46—85) 50 (38—106)
Lung cancer 1 108 79 790
Other non-HIV conditions
Cardiac complications 3 136 (115—199) 91 (60—123) 162 (158—166)
Viral myocarditis 1 3 65 NAa
a CD4 cell count at the time of initiating HAART and/or at the time of death was not available.
e130 N. Kumarasamy et al.found that despite similar virological and immunological
responses at both settings, patients in low-income countries
started therapy with considerably more advanced immuno-
deficiency.9 Increasingly HIV-infected patients are gaining
access to life-saving antiretrovirals across the developing
world, however greater efforts must be made via proactive
voluntary counseling and testing to identify HIV-infected
patients and to then consequently initiate HAART amongFigure 1 Kaplan—Meier survival estimate after initiating
HAART.patients meeting treatment criteria in order to minimize a
still too high AIDS-associated mortality.
Initiating patients on ART is never a medical emergency,
but providing prompt early treatment for opportunistic infec-
tions can avert patient deaths. With the expanded provision
of ART, it is possible that tuberculosis screening, prevention,
and treatment can be combined with the provision of HIV
care.24,25 A related question is whether HAART should be
initiated earlier than current guidelines for the purpose of
optimizing survival.26 Randomized trials are needed among
HIV-infected patients with advanced immunodeficiency who
may also have a high possibility of undetected opportunistic
infections to examine if empirical anti-tuberculosis therapy
and treatment for other common opportunistic infections
will be beneficial along with the provision of HAART.
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